Related Experiment Video

Updated: Jun 13, 2026

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

mTOR signaling in glioblastoma: lessons learned from bench to bedside

David Akhavan1, Timothy F Cloughesy, Paul S Mischel

  • 1The David Geffen UCLA School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732, USA.

Neuro-Oncology
|May 18, 2010
PubMed

Insights

Hyperactivated phosphatidyl-inositol-3 kinases (PI3K) signaling drives glioblastoma. This review explores the role of the mammalian target of rapamycin (mTOR) pathway in glioblastoma, including resistance mechanisms and future therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Phosphatidyl-inositol-3 kinases (PI3Ks) are intracellular lipid kinases crucial for cell signaling.
  • PI3K pathway hyperactivation is common in glioblastoma, a deadly brain cancer.
  • The PI3K pathway regulates fundamental cellular processes like proliferation, metabolism, and survival.

Purpose of the Study:

  • To review the critical role of the mammalian target of rapamycin (mTOR) in glioblastoma.
  • To discuss mechanisms by which glioblastoma cells evade mTOR inhibition.
  • To outline future clinical strategies for targeting the mTOR pathway in glioblastoma treatment.

Main Methods:

  • Literature review of laboratory studies on mTOR in glioblastoma.
  • Analysis of clinical trial data investigating mTOR inhibitors.
  • Examination of preclinical models to understand resistance mechanisms.

Main Results:

  • The PI3K/mTOR pathway is a key driver of glioblastoma growth and survival.
  • mTOR acts as both a downstream target and upstream regulator within the PI3K pathway.
  • Evidence supports mTOR's significant role in glioblastoma pathogenesis.

Conclusions:

  • Targeting the mTOR pathway presents a promising therapeutic avenue for glioblastoma.
  • Understanding resistance mechanisms is crucial for developing effective mTOR-targeted therapies.
  • Future strategies should focus on combination therapies and novel mTOR inhibitors for glioblastoma.

More Related Videos

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...